Moreover, a previous study showed that the MDM2-targeted PROTAC degrader may potentially outperform the current MDM2 inhibitors in treating triple-negative breast cancer (TNBC), a type of cancer characterized by inactivation of the p53 tumor suppressor protein. This evidence concerns the gene TP53 and cancer.